Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory ...
Arcus Biosciences develops and advances oncology therapies, including Etrumadenant (A2a/A2b antagonist), Zimberelimab (anti-PD-1 antibody), Domvanalimab (anti-TIGIT antibody), Quemliclustat (CD73 ...
Zacks Investment Research on MSN
Arcus, Bristol Myers team up to advance kidney cancer study
Arcus Biosciences RCUS announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMY to ...
Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear cell renal cell carcinoma (ccRCC) This is the second ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Arcus outlines development strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including the potential to become the first ...
At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing ...
Arcus Biosciences has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer. The drug, casdatifan, will be ...
Councils accelerating consolidation onto unified cloud platforms across departments We built Arcus Global to give ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results